Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xarelto | Rivaroxaban | Venous thromboembolic events, pulmonary embolism | List with criteria/condition | Complete | ||
| Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete | ||
| Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Stivarga (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
| Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 18, 2024